Viridian Therapeutics (VRDN) Competitors $20.14 -1.50 (-6.93%) (As of 11/15/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends VRDN vs. ARWR, PMD, OPGN, DRNA, SHC, GH, OPCH, BTSG, SGRY, and PACSShould you be buying Viridian Therapeutics stock or one of its competitors? The main competitors of Viridian Therapeutics include Arrowhead Pharmaceuticals (ARWR), Psychemedics (PMD), OpGen (OPGN), Dicerna Pharmaceuticals (DRNA), Sotera Health (SHC), Guardant Health (GH), Option Care Health (OPCH), BrightSpring Health Services (BTSG), Surgery Partners (SGRY), and PACS Group (PACS). These companies are all part of the "medical" sector. Viridian Therapeutics vs. Arrowhead Pharmaceuticals Psychemedics OpGen Dicerna Pharmaceuticals Sotera Health Guardant Health Option Care Health BrightSpring Health Services Surgery Partners PACS Group Viridian Therapeutics (NASDAQ:VRDN) and Arrowhead Pharmaceuticals (NASDAQ:ARWR) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, community ranking, risk, earnings, profitability, media sentiment, institutional ownership, dividends and analyst recommendations. Do insiders & institutionals believe in VRDN or ARWR? 62.6% of Arrowhead Pharmaceuticals shares are owned by institutional investors. 0.7% of Viridian Therapeutics shares are owned by insiders. Comparatively, 4.5% of Arrowhead Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Which has stronger valuation & earnings, VRDN or ARWR? Arrowhead Pharmaceuticals has higher revenue and earnings than Viridian Therapeutics. Viridian Therapeutics is trading at a lower price-to-earnings ratio than Arrowhead Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioViridian Therapeutics$310K5,146.09-$237.73M-$4.31-4.67Arrowhead Pharmaceuticals$240.74M9.59-$205.27M-$4.67-3.98 Do analysts prefer VRDN or ARWR? Viridian Therapeutics currently has a consensus target price of $36.33, suggesting a potential upside of 80.40%. Arrowhead Pharmaceuticals has a consensus target price of $45.33, suggesting a potential upside of 144.12%. Given Arrowhead Pharmaceuticals' higher possible upside, analysts clearly believe Arrowhead Pharmaceuticals is more favorable than Viridian Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Viridian Therapeutics 0 Sell rating(s) 2 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 2.80Arrowhead Pharmaceuticals 0 Sell rating(s) 3 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.70 Is VRDN or ARWR more profitable? Arrowhead Pharmaceuticals has a net margin of 0.00% compared to Viridian Therapeutics' net margin of -85,127.16%. Viridian Therapeutics' return on equity of -70.12% beat Arrowhead Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Viridian Therapeutics-85,127.16% -70.12% -41.49% Arrowhead Pharmaceuticals N/A -152.95%-63.93% Does the media refer more to VRDN or ARWR? In the previous week, Viridian Therapeutics had 28 more articles in the media than Arrowhead Pharmaceuticals. MarketBeat recorded 32 mentions for Viridian Therapeutics and 4 mentions for Arrowhead Pharmaceuticals. Arrowhead Pharmaceuticals' average media sentiment score of 0.88 beat Viridian Therapeutics' score of 0.22 indicating that Arrowhead Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Viridian Therapeutics 5 Very Positive mention(s) 7 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Arrowhead Pharmaceuticals 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Does the MarketBeat Community prefer VRDN or ARWR? Arrowhead Pharmaceuticals received 470 more outperform votes than Viridian Therapeutics when rated by MarketBeat users. However, 78.16% of users gave Viridian Therapeutics an outperform vote while only 65.37% of users gave Arrowhead Pharmaceuticals an outperform vote. CompanyUnderperformOutperformViridian TherapeuticsOutperform Votes6878.16% Underperform Votes1921.84% Arrowhead PharmaceuticalsOutperform Votes53865.37% Underperform Votes28534.63% Which has more volatility and risk, VRDN or ARWR? Viridian Therapeutics has a beta of 1.1, suggesting that its share price is 10% more volatile than the S&P 500. Comparatively, Arrowhead Pharmaceuticals has a beta of 0.93, suggesting that its share price is 7% less volatile than the S&P 500. SummaryViridian Therapeutics and Arrowhead Pharmaceuticals tied by winning 9 of the 18 factors compared between the two stocks. Ad Insiders ExposedHas Trump Finally Gone Too Far?Lately, there's been a lot of buzz around a secret loophole executive insiders are using to make millions buying and selling their own stocks. It's so powerful ... so profitable ... that most people immediately assume this is just another example of Trump doing what's best for business executives. But surprisingly, this loophole has been on the books for many years and executives have been using it to make HUNDREDS of millions of dollars. And here's the good news.Register For The Webinar To Discover Get Viridian Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for VRDN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VRDN vs. The Competition Export to ExcelMetricViridian TherapeuticsMedical laboratories IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.60B$2.84B$5.15B$8.74BDividend YieldN/A1.72%5.18%4.08%P/E Ratio-4.679.7366.3713.55Price / Sales5,146.09211.141,276.8487.67Price / CashN/A373.0039.7035.24Price / Book3.072.996.475.93Net Income-$237.73M-$32.88M$119.73M$225.73M7 Day Performance-20.11%-5.71%-5.13%-1.34%1 Month Performance-16.98%-4.39%-2.71%1.15%1 Year Performance26.83%21.23%31.08%24.02% Viridian Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VRDNViridian Therapeutics2.4182 of 5 stars$20.14-6.9%$36.33+80.4%+32.5%$1.60B$310,000.00-4.6750Earnings ReportAnalyst ForecastAnalyst RevisionNews CoverageARWRArrowhead Pharmaceuticals3.714 of 5 stars$21.63+0.6%N/A-28.7%$2.69B$240.74M-4.63400Analyst UpgradeNews CoveragePMDPsychemedics0.7642 of 5 stars$2.34flatN/A+9.9%$13.79M$20.79M-4.59140Short Interest ↓News CoverageHigh Trading VolumeOPGNOpGenN/A$1.49+6.5%N/A-57.6%$12.41M$2.67M0.00100Analyst ForecastDRNADicerna Pharmaceuticals1.0976 of 5 stars$38.22flatN/AN/A$2.99B$164.31M-23.45302SHCSotera Health3.909 of 5 stars$15.32-1.4%N/A+4.1%$4.34B$1.05B61.283,000Positive NewsGHGuardant Health4.7375 of 5 stars$31.61+6.3%N/A+30.2%$3.91B$563.95M-7.461,779Short Interest ↓OPCHOption Care Health4.9795 of 5 stars$22.18-2.9%N/A-24.6%$3.77B$4.30B18.647,802Insider BuyingShort Interest ↓News CoveragePositive NewsBTSGBrightSpring Health Services2.9824 of 5 stars$19.66+0.6%N/AN/A$3.42B$8.83B-75.6235,000Short Interest ↓Positive NewsSGRYSurgery Partners3.1201 of 5 stars$25.51-13.8%N/A-25.5%$3.24B$2.89B-53.1413,500Earnings ReportAnalyst ForecastNews CoverageHigh Trading VolumePACSPACS Group3.4438 of 5 stars$20.49-0.2%N/AN/A$3.12B$3.11B0.0032,433News Coverage Related Companies and Tools Related Companies ARWR Competitors PMD Competitors OPGN Competitors DRNA Competitors SHC Competitors GH Competitors OPCH Competitors BTSG Competitors SGRY Competitors PACS Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:VRDN) was last updated on 11/17/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredThere is a little known company that is changing warfareWith geo - political instability around the world investors are flocking to defense contract stocks. There...Reticulate | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Viridian Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Viridian Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free VRDN Stock Alerts